These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 38324115)
1. Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment. Rajaeinejad M; Parhizkar-Roudsari P; Khoshfetrat M; Kazemi-Galougahi MH; Mosaed R; Arjmand R; Mohsenizadeh SA; Arjmand B Cardiovasc Toxicol; 2024 Feb; 24(2):184-198. PubMed ID: 38324115 [TBL] [Abstract][Full Text] [Related]
2. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal. Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619 [TBL] [Abstract][Full Text] [Related]
3. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468 [TBL] [Abstract][Full Text] [Related]
4. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220 [TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506 [TBL] [Abstract][Full Text] [Related]
8. Fluoropyrimidine-associated cardiotoxicity: revisited. Saif MW; Shah MM; Shah AR Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247 [TBL] [Abstract][Full Text] [Related]
9. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649 [No Abstract] [Full Text] [Related]
10. 5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death. More LA; Lane S; Asnani A Curr Cardiol Rep; 2021 Feb; 23(3):17. PubMed ID: 33537861 [TBL] [Abstract][Full Text] [Related]
11. Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity. Saif MW Onco Targets Ther; 2020; 13():10197-10206. PubMed ID: 33116601 [TBL] [Abstract][Full Text] [Related]
12. The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease. Fabin N; Bergami M; Cenko E; Bugiardini R; Manfrini O J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268333 [TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Schöber C; Papageorgiou E; Harstrick A; Bokemeyer C; Mügge A; Stahl M; Wilke H; Poliwoda H; Hiddemann W; Köhne-Wömpner CH Cancer; 1993 Oct; 72(7):2242-7. PubMed ID: 8374883 [TBL] [Abstract][Full Text] [Related]
14. Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator. Abiodun A; Shawe-Taylor M; Tyebally S; Bagkeris E; Bajomo O; Artico J; Slater S; Raisi-Estabragh Z; Diamantis N; Manisty C ESC Heart Fail; 2024 Oct; 11(5):3041-3051. PubMed ID: 38845140 [TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of the antiproliferative compound fluorouracil. Becker K; Erckenbrecht JF; Häussinger D; Frieling T Drugs; 1999 Apr; 57(4):475-84. PubMed ID: 10235688 [TBL] [Abstract][Full Text] [Related]
16. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge. Vater LB; Lefebvre B; Turk A; Clasen SC Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593 [TBL] [Abstract][Full Text] [Related]
17. [Cardiotoxicity of 5-fluorouracil]. Pan L; Yang X; Song H Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):86-9. PubMed ID: 8758800 [TBL] [Abstract][Full Text] [Related]
18. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. Khan MA; Masood N; Husain N; Ahmad B; Aziz T; Naeem A J Pak Med Assoc; 2012 May; 62(5):430-4. PubMed ID: 22755303 [TBL] [Abstract][Full Text] [Related]
19. Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study. Dyhl-Polk A; Schou M; Vistisen KK; Sillesen AS; Serup-Hansen E; Faber J; Klausen TW; Bojesen SE; Vaage-Nilsen M; Nielsen DL Oncologist; 2021 Mar; 26(3):e403-e413. PubMed ID: 32959474 [TBL] [Abstract][Full Text] [Related]
20. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series. Saif MW; Garcon MC; Rodriguez G; Rodriguez T In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]